ADVISORY, Nov. 4, 2011 (GLOBE NEWSWIRE) --
What:
NPS Pharmaceuticals (Nasdaq:NPSP) a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options, will visit the NASDAQ MarketSite in New York City's Times Square.
In honor of the occasion Francois Nader, President & CEO will ring the Opening Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Monday, November 7th, 2011 – 9:15 a.m. to 9:30 a.m. ET
Contacts:
Tony Plohoros
6 Degrees PR
(908) 591.2839 (mobile)
tplohoros@6degreesPR.com
Susan Mesco
NPS Pharmaceuticals
(908) 391-8283
smesco@npsp.com
NASDAQ MarketSite:
Jen Knapp
(212) 401-8916
Jennifer.knapp@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Media): 4463
Can also be found on Satellite:
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC ¾
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
If you have any questions, please contact Jen Knapp (212) 401-8916.
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/nasdaqomx
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About NPS Pharmaceuticals, Inc. [NPSP]:
NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company is advancing two Phase 3 registration programs, GATTEX(R) (teduglutide) in short bowel syndrome (SBS) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).
-NDAQA-